logo image
search icon
Global Etanercept Biosimilar Market

Etanercept Biosimilar Market Size, Share & Trends Analysis Report By Applications (Rheumatoid Arthritis, Juvenile Rheumatoid Arthritis, Psoriatic Arthritis, Plaque Psoriasis, And Ankylosing Spondylitis), Distribution Channel, Region And Segment Forecasts, 2023-2031.

Report ID : 1068 | Published : 2023-07-12 | Pages: 180 | Format: PDF/EXCEL

The Etanercept Biosimilar Market Size is valued at XX Million in 2022 and is predicted to reach XX Million by the year 2031 at an XX % CAGR during the forecast period for 2023-2031.

Etanercept Biosimilar Market

Etanercept is a tumor necrosis factor alpha (TNF-α) inhibitor, an important inflammatory disease mediator in various articular diseases. Etanercept was the first tumour necrosis factor-alpha (TNF-α) inhibitor approved for the treatment of rheumatoid arthritis. It is also approved for the treatment of juvenile rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, and ankylosing spondylitis. Etanercept competitively inhibits the binding of TNF to cell surface receptors and thus makes TNF biologically inactive. By doing so, the drug inhibits the pro-inflammatory effects of TNF and thereby leads in a reduction of joint inflammation. Etanercept was developed and marketed by Amgen and Pfizer. The drug was approved by the U.S. Food Drug and Administration in November 1998. It was approved in Europe by European Medicines Agency in February 2000. It is marketed under the trade name of ‘Enbrel’.

Expiration of patent and near-term expiration of patent has led to the entry of biosimilar into the market. The patent of Enbrel is expired in Europe in August 2015 and will expire in the U.S. in November 2028. Biosimilar is defined as a type of biological product that is approved by respective regulatory bodies because of its clinical similarity to already approved biological products. Reducing treatment cost is the principal attraction factor for the growth of etanercept biosimilars market. Thus many of biosimilar of etanercept are currently approved and some are in development phase which are expected to come into the market during forecast period. Introduction to biosimilars, increase in incidence and prevalence rate of various articular diseases, and rising demand for cost effective alternatives are the factors boosted the growth of etanercept biosimilar market. However, stringent regulatory process for the approval of etanercept biosimilar and complicated manufacturing process are the major restrain factors for the growth of the etanercept biosimilar market.

Market Segmentation

The global etanercept biosimilar market is segmented on the basis of application, distribution channel and geography. Based on the application global etanercept biosimilar market is segmented into rheumatoid arthritis, juvenile rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, and ankylosing spondylitis. Rheumatoid arthritis segment is expected to grow at higher pace during the forecast period owing to increasing incidence and prevalence rate. Based on distribution channel the global etanercept biosimilar market is segmented as hospital pharmacy, online pharmacy and others. Online pharmacy segment is expected to grow during forecast period due to increase in number of internet users and ease of use.

Geographically, the global etanercept biosimilar market has been segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. In terms of revenue, Europe followed by Asia Pacific is major contributor for the global etanercept biosimilar market. This is because early patent expiry, entry of etanercept biosimilars, strong clinical pipeline, increasing research and drug development activities, presence of major players, and developing healthcare infrastructure propels the growth of the market in the region. Asia Pacific is promising revenue contributor which is expected to grow at rapid pace in upcoming year. Countries such as Japan, India and China are major contributors for this market. Huge population base in countries such as China and India offers tremendous market opportunities for the etanercept biosimilar market. North America is third major contributor for the market in forecast period and is expected to grow at rapid pace, due to presence of strong clinical pipeline.

Competitive Landscape

Some of The Key Players in The Etanercept Biosimilar Market:

  • Avesthagen
  • Cipla
  • LG Life Sciences
  • Protalix Biotherapeutics
  • BioXpress Therapeutics
  • Sandoz
  • Celltrion
  • Teva Pharmaceutical Industries
  • Pfizer
  • Samsung Bioepis
  • mAbxience
  • Other Prominent Players

The Etanercept Biosimilar Market Report Scope

Report Attribute

Specifications

Market Size Value In 2022

USD XX Million

Revenue Forecast In 2031

USD XX Million

Growth Rate CAGR

CAGR of XX % from 2023 to 2031

Quantitative Units

Representation of revenue in US$ Million and CAGR from 2023 to 2031

Historic Year

2019 to 2022

Forecast Year

2023-2031

Report Coverage

The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends

Segments Covered

By Applications, By Distribution Channel

Regional Scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country Scope

U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia

Competitive Landscape

Avesthagen, Cipla, LG Life Sciences, Protalix Biotherapeutics, BioXpress Therapeutics, Sandoz, Celltrion, Teva Pharmaceutical Industries, Pfizer, Samsung Bioepis, mAbxience, and Others

Customization Scope

Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape.

Pricing and Available Payment Methods

Explore pricing alternatives that are customized to your particular study requirements.

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Etanercept Biosimilar Market Snapshot

Chapter 4. Global Etanercept Biosimilar Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 1: By Applications Estimates & Trend Analysis

5.1. By Applications & Market Share, 2022 & 2030

5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2030 for the following By Applications:

5.2.1. Rheumatoid arthritis

5.2.2. Juvenile rheumatoid arthritis

5.2.3. Psoriatic arthritis

5.2.4. Plaque psoriasis

5.2.5. Ankylosing spondylitis

Chapter 6. Market Segmentation 2: By Distribution Channel Estimates & Trend Analysis

6.1. By Distribution Channel & Market Share, 2022& 2030

6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2030 for the following By Distribution Channel:

6.2.1. Hospital Pharmacy

6.2.2. Online Pharmacy

6.2.3. Retail Pharmacy

6.2.4. Other Direct Distribution Channels

Chapter 7. Etanercept Biosimilar Market Segmentation 3: Regional Estimates & Trend Analysis

7.1. North America

7.1.1. North America Etanercept Biosimilar Market revenue (US$ Million) estimates and forecasts By Applications, 2022 - 2030

7.1.2. North America Etanercept Biosimilar Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2022 - 2030

7.1.3. North America Etanercept Biosimilar Market revenue (US$ Million) estimates and forecasts by country, 2022 - 2030

7.2. Europe

7.2.1. Europe Etanercept Biosimilar Market revenue (US$ Million) By Applications, 2022 - 2030

7.2.2. Europe Etanercept Biosimilar Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2022 - 2030

7.2.3. Europe Etanercept Biosimilar Market revenue (US$ Million) by country, 2022 - 2030

7.3. Asia Pacific

7.3.1. Asia Pacific Etanercept Biosimilar Market revenue (US$ Million) By Applications, 2022 - 2030

7.3.2. Asia Pacific Etanercept Biosimilar Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2022 - 2030

7.3.3. Asia Pacific Etanercept Biosimilar Market revenue (US$ Million) by country, 2022 - 2030

7.4. Latin America

7.4.1. Latin America Etanercept Biosimilar Market revenue (US$ Million) By Applications, (US$ Million)

7.4.2. Latin America Etanercept Biosimilar Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2022 - 2030

7.4.3. Latin America Etanercept Biosimilar Market revenue (US$ Million) by country, (US$ Million) 2022 - 2030

7.5. Middle East & Africa

7.5.1. Middle East & Africa Etanercept Biosimilar Market revenue (US$ Million) By Applications, (US$ Million)

7.5.2. Middle East & Africa Etanercept Biosimilar Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2022 - 2030

7.5.3. Middle East & Africa Etanercept Biosimilar Market revenue (US$ Million) by country, (US$ Million) 2022 - 2030

Chapter 8. Competitive Landscape

8.1. Major Mergers and Acquisitions/Strategic Alliances

8.2. Company Profiles 

8.2.1. Avesthagen

8.2.2. Cipla

8.2.3. LG Life Sciences

8.2.4. Protalix Biotherapeutics

8.2.5. BioXpress Therapeutics

8.2.6. Sandoz

8.2.7. Celltrion

8.2.8. Teva Pharmaceutical Industries

8.2.9. Pfizer

8.2.10. Samsung Bioepis

8.2.11. mAbxience

8.2.12. Other Prominent Player 

Global Etanercept Biosimilar Market Segmentation

Global Etanercept Biosimilar Market Outlook  By Application

  • Rheumatoid arthritis
  • Juvenile rheumatoid arthritis
  • Psoriatic arthritis
  • Plaque psoriasis
  • Ankylosing spondylitis

Etanercept Biosimilar Market

Global Etanercept Biosimilar Market Outlook  By Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy
  • Other Direct Distribution Channels

Global Etanercept Biosimilar Market Outlook  By Region

  • Europe
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • North America
    • U.S.
    • Canada
  • Asia Pacific
    • India
    • China
    • Japan
    • South Korea
    • Australia & New Zealand
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
    • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

user icon
office icon
mail icon
call icon

This website is secure, and we do not share your personal information with any third party. Privacy Policy

Need Customization
Need specific information/chapter from the report of the custom data table, graph or complete report? Tell us more.

Frequently Asked Questions

How big is the Etanercept Biosimilar Market Size?

The Etanercept Biosimilar Market is expected to grow at an XX % CAGR during the forecast period for 2023-2031.

Avesthagen, Cipla, LG Life Sciences, Protalix Biotherapeutics, BioXpress Therapeutics, Sandoz, Celltrion, Teva Pharmaceutical Industries, Pfizer, Sams

Our Clients

  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo

Media Citations

  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo

Growth opportunities and latent adjacency in Pharmaceuticals

Select Licence Type
$3786
$5786
$7786
$1200
Get Your GTM Strategy

Navigate market entry with channel selection, launch strategy & timeline, and pricing model support.

Equip yourself with the insights needed to develop a winning go-to-market strategy

Get real-time updates and joint control over project direction with our collaborative approach